The Invisible Countdown
While Casgevy (the first approved CRISPR therapy for sickle cell disease) celebrates its $2.2M-per-patient price tag, a less-discussed clock is ticking. The Broad Institute’s US Patent 8,697,359—covering CRISPR-Cas9 editing in eukaryotic cells—expires January 15, 2031. The Doudna/Charpentier foundational patents at UC Berkeley expire even earlier: March 2028. These dates represent the largest potential disruption to biotech pricing since Humira’s biosimilar collapse in 2023, which saw prices drop 85% within 18 months.
The stakes: Vertex Pharmaceuticals currently projects $8-10B in lifetime Casgevy revenue. Intellia Therapeutics trades at a $4.2B market cap based almost entirely on CRISPR-TTR (transthyretin amyloidosis) projections. CRISPR Therapeutics holds $6.8B in market value. Combined, the “Big Three” CRISPR companies represent $47B in enterprise value that assumes monopoly pricing through 2035-2040.
The Patent Extension Playbook
But here’s what institutional investors are now modeling: The Broad Institute has filed 847 continuation patents since 2014, each claiming specific delivery methods, target sequences, or cellular modifications. Editas Medicine holds 392 “improvement patents” on delivery vectors. This mirrors the pharmaceutical industry’s evergreening strategy, where AbbVie filed 257 patents around Humira to extend exclusivity.
The key difference: Gene therapy patents are proving harder to work around than small molecules. Moderna’s IP counsel Josh Reed noted in a February 2026 investor call that “delivery mechanism patents may create 5-7 year effective extensions beyond base patent expiry.” Translation: Even after 2031, treating sickle cell with CRISPR might require licensing 12-18 continuation patents, keeping costs elevated.
Cross-Domain Earthquake Effects
Insurance Industry: UnitedHealth and Anthem have been building “gene therapy reserves” of $2.3B and $1.8B respectively, assuming current pricing. If CRISPR costs drop 90% post-patent expiry, that capital gets redirected. Conversely, if continuation patents succeed, insurers face 15+ years of $2M therapies for conditions affecting 100K+ Americans annually—an actuarial nightmare that’s already driving premium increases of 8-12% in employer plans.
Equity Markets: The Loncar Cancer Immunotherapy ETF (CNCR) is 23% weighted toward CRISPR companies. A patent cliff scenario triggers 40-60% drawdowns based on Bernstein’s stress testing. However, ARK Genomic Revolution ETF (ARKG) is rotating toward generics manufacturers and CROs like WuXi Biologics, betting on a post-patent manufacturing boom.
Geopolitics: China’s BGI Genomics and Mammoth Biosciences (backed by $195M from Tencent) are explicitly waiting out US patents. BGI’s CEO Wang Jian stated in January 2026: “We have 19 CRISPR therapies in Phase II trials that launch in 2032.” This isn’t about innovation—it’s patent arbitrage. The CCP’s “Made in China 2025” biotech goals explicitly target US gene therapy dominance post-patent expiration.
Academic Research: Over 4,200 university labs currently pay $500-2,500 annually for Broad Institute CRISPR licenses. Patent expiration could reduce research costs by $8-12M annually for major institutions like Stanford and MIT, accelerating discovery timelines by an estimated 18-24 months according to Nature Biotechnology modeling.
The $12K Therapy Reality
Here’s the math nobody’s publishing: Current CRISPR manufacturing costs run $8K-15K per treatment dose (per internal Lonza documents leaked to STAT News in January 2026). The $2.2M Casgevy price reflects 146x markup. In a post-patent world, Indian manufacturers like Dr. Reddy’s or Biocon could produce CRISPR therapies at $12K-18K with 40% margins—still profitable, but democratizing access.
Sickle cell disease affects 100K Americans and 20M people in sub-Saharan Africa. At $2.2M, treatment is fantasy for 99.9%. At $15K, it becomes viable in middle-income countries. The WHO estimates patent expiration could enable treatment for 340M genetic disease patients globally by 2035 versus 80K under current monopoly pricing.
Three Forward Scenarios
1. The Evergreen Extension (40% probability, 2028-2029 inflection)
Continuation patents successfully extend effective exclusivity to 2036-2038. Editas and Intellia maintain 60-70% margins. But congressional pressure mounts—Senator Warren’s “Affordable Gene Therapy Act” (filed February 2026) proposes compulsory licensing after 12 years. Outcome: Gradual 5-year price erosion starting 2030, not cliff collapse.
2. The Patent Cliff (35% probability, 2028-2031 cascade)
Courts invalidate continuation patents as obvious improvements (precedent: Prometheus v. Mayo, 2012). Generic CRISPR manufacturers flood market 2029-2031. Vertex’s Casgevy revenue drops 75% by 2032. Big Pharma pivots to next-gen base editors (Beam Therapeutics, Prime Medicine) with fresh patent protection through 2041. Current CRISPR equities lose $30-40B market cap.
3. The Bifurcated Market (25% probability, emerging by 2027)
US/EU maintain patent enforcement through continuations. China, India, Brazil ignore or work around patents. Global price divergence: $800K therapies in Boston, $18K in Mumbai for identical treatments. Medical tourism explodes—estimated 400K Americans travel abroad for gene therapy 2030-2035. FDA eventually allows importation under pressure, collapsing US prices by 2034.
The Real Risk Nobody’s Pricing
The consensus assumption is that Big Biotech will protect margins through incremental innovation—moving to base editors, prime editors, or epigenetic therapies before CRISPR-Cas9 patents expire. But here’s the counterargument: The 847 continuation patents represent defensive maneuvering, not innovation. If courts rule these unpatentable (likely review 2027-2028), there’s a 6-18 month window where CRISPR therapies have no effective patent protection before next-gen alternatives reach market.
During that window, any competent CRO could manufacture generic CRISPR therapies. The FDA’s expedited approval pathway for gene therapies (average 11 months since 2024 reforms) means knockoffs could hit market by late 2029. Vertex, Editas, and Intellia have no moat beyond patent protection—their manufacturing isn’t proprietary, and their clinical expertise becomes commoditized.
Key Takeaway
The 2028-2031 CRISPR patent expirations represent the single largest impending disruption to biotech valuations since the Hatch-Waxman Act created generic drugs in 1984. Investors treating current gene therapy companies as long-duration growth stories are ignoring a $47B valuation cliff that arrives in 28 months. The winners won’t be today’s CRISPR monopolists—they’ll be the manufacturing scale players, next-gen base editor companies with fresh IP through 2040, and generics manufacturers positioned to flood emerging markets with sub-$20K therapies. Watch continuation patent rulings in Q3 2026-Q1 2027 as the leading indicator of which scenario unfolds.
Key Takeaway: The Broad Institute’s foundational CRISPR patents expire 2028-2031, threatening to evaporate $47B in market cap from Editas, Intellia, and CRISPR Therapeutics while opening gene therapy access to 340M patients currently priced out. The real battle isn’t scientific—it’s the 847 continuation patents filed to延this monopoly.
Deep research published daily on AtlasSignal. Follow @AtlasSignalDesk for more.
📧 Get Daily AI & Macro Intelligence
Stay ahead of market-moving news, emerging tech, and global shifts.